10-Q: AbCellera Biologics Inc. Reports Second Quarter 2024 Results: Revenue Declines Amidst Increased R&D Spending and Strategic Investments

AbCellera Biologics Inc. reported a decrease in revenue for the second quarter of 2024, alongside increased operating expenses primarily driven by research and development and a significant impairment charge.

Summary

• AbCellera Biologics Inc. reported a net loss of $36.9 million for the three months ended June 30, 2024, and a net loss of $77.5 million for the six months ended June 30, 2024.
• Total revenue decreased to $7.3 million for the quarter and $17.3 million for the six-month period, primarily due to a decline in research fees.
• Operating expenses increased to $100.8 million for the quarter and $165.6 million for the six-month period, driven by higher research and development costs and a $32 million impairment charge related to IPR&D.
• The company's cash, cash equivalents, and marketable securities totaled $670.4 million as of June 30, 2024, a decrease of $90.2 million since December 31, 2023.
• AbCellera has advanced two internal programs into IND-enabling studies and has a cumulative total of 93 partner-initiated programs with downstream participation, with 14 molecules advanced into the clinic.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in partnerships and pipeline progress, the financial results show a significant loss and revenue decline, which is concerning. The high R&D spending and impairment charge also contribute to a negative sentiment.

Positives

• AbCellera has secured significant government co-investments to help fund research and development, including internal programs, and facility construction.
• The company has advanced two AbCellera-led programs into IND-enabling studies.
• AbCellera has a cumulative total of 93 partner-initiated programs with downstream participation.
• The company has seen a cumulative total of 14 molecules advanced into the clinic.
• AbCellera believes its available liquidity will be sufficient to meet its working capital and capital expenditure needs for at least the next 36 months.

Negatives

• AbCellera experienced a 27% decrease in total revenue for the three months ended June 30, 2024, compared to the same period in 2023.
• The company's operating expenses increased by 64% to $100.8 million for the quarter, primarily due to a $32 million impairment charge on intangible assets.
• The company reported a net loss of $36.9 million for the quarter and $77.5 million for the six months ended June 30, 2024.
• AbCellera's cash, cash equivalents, and marketable securities decreased to $670.4 million as of June 30, 2024, from $760.6 million at the end of 2023.

Risks

• The company has incurred losses in certain years since inception, including in 2023 and 2024, and may not be able to generate sufficient revenue to achieve profitability.
• Quarterly and annual operating results have fluctuated significantly in the past and may fluctuate significantly in the future, making future results difficult to predict.
• Unstable market and economic conditions may have serious adverse consequences on the business, financial condition, and stock price.
• Commercial success depends on the quality of the antibody discovery and development engine and technological capabilities, the advancement of internal programs, and their acceptance by new and existing partners.
• Failure to execute the business strategy could adversely impact growth and profitability.
• The company may be unable to manage current and future growth effectively, which could make it difficult to execute on the business strategy.
• Investments in research and development efforts are inherently risky and may affect operating results.
• Partners have significant discretion in determining when and whether to make announcements about the status of partnerships, which could cause the share price to decline.
• Partners may not achieve projected discovery and development milestones in the expected timelines or at all, which could have an adverse impact on the business.
• The company may not be able to file INDs or IND amendments to commence additional clinical trials on the timelines expected, and even if able to, the FDA may not permit them to proceed.
• The life sciences and biotechnology platform technology market is highly competitive.
• Upgrading and integrating business systems could result in implementation issues and business disruptions.
• Failure to maintain proper and effective internal control over financial reporting could harm operating results and the ability to operate the business.
• Sales of a substantial number of common shares in the public market could cause the share price to fall significantly.

Future Outlook

Based on the current business plan, the company believes that its available liquidity from existing cash, cash equivalents, marketable securities, loan receivables, and government contributions will be sufficient to meet its working capital and capital expenditure needs and does not anticipate the need for additional external funding over at least the next 36 months.

Management Comments

• The company is focused on the development of antibody-based drugs and is committed to improving discovery and development.
• AbCellera aims to build a competitive advantage in bringing antibody therapeutics from target into clinical testing by combining expertise, technologies, and infrastructure.
• The company thinks deeply about capital allocation and strives to maximize long-term value while mitigating the risks that are inherent in drug development and in scaling a company.
• AbCellera structures agreements in a way that is designed to align partners' economic interests with its own.
• The company is strategically leveraging its engine to develop internal programs to address areas of high unmet medical need and to advance its pipeline of first-in-class and best-in-class medicines.

Industry Context

The announcement reflects the ongoing challenges and investments in the biotechnology sector, particularly in antibody drug discovery and development. The company's focus on technology and strategic partnerships aligns with industry trends, but the financial results highlight the inherent risks and volatility in this space. The expanded collaboration with Lilly and the Invetx acquisition are positive developments, but the overall financial performance indicates the need for continued progress in advancing programs and generating revenue.

Comparison to Industry Standards

• AbCellera's revenue decline contrasts with some larger, more established biotech companies that have diversified revenue streams.
• The increase in R&D spending is typical for companies in the clinical stage of development, but the significant impairment charge is a notable negative.
• The company's cash position is strong compared to many smaller biotech firms, but the burn rate is a concern.
• The number of partner-initiated programs and molecules in the clinic is a positive indicator of future potential, but the timeline for commercialization remains uncertain.
• Compared to companies like Adimab and Distributed Bio, AbCellera's business model is more focused on downstream participation, which can lead to higher potential returns but also greater risk.

Legal Proceedings

• The District Court lifted the stay in the pending matter against Bruker Cellular Analysis, and the case has resumed.
• Bruker Cellular Analysis filed a Notice of Appeal in IPR2021-1249 matter, which the company believes is meritless.
• The company filed a Notice of Application seeking to dismiss certain company affiliates from the matter Sabariah Schrader, Executrix of the Estate of John William Schrader et al. v. Carl Lars Genghis Hansen, et al.

Stakeholder Impact

• Shareholders may be concerned about the decreased revenue and increased losses, as well as the decrease in cash and marketable securities.
• Employees may be affected by the restructuring and reorganization activities.
• Customers and partners may be impacted by the company's ability to deliver on its programs and partnerships.
• Creditors may be concerned about the company's financial performance and ability to repay debts.

Next Steps

• Continue to invest in research and development activities to improve the antibody discovery and development engine.
• Pursue internal and co-development programs in preclinical and eventually clinical development.
• Market and sell solutions to existing and new strategic partners.
• Expand and enhance operations to deliver programs, including investments in manufacturing.
• Continue to establish, protect and defend intellectual property and patent portfolio.

Key Dates

Keywords

antibody discovery, biologics, drug development, research and development, clinical trials, pharmaceutical partnerships, biotechnology, therapeutic antibodies, revenue, financial results